Our results indicated that treatment of refractory or relapsed advanced NSCLC with either Atz or Niv monotherapy was more effective than treatment with Doc or Ram+Doc for patients lacking the PD-L1 status constraint. This evidence concerns the gene CD274 and non-small cell lung carcinoma.